[18F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis

IF 1.8 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Helena A. Peters , Ben-Niklas Bärmann , Emil Novruzov , Daniel Weiss , Matthias Boschheidgen , Vivien Lorena Ivan , Nora Liebers , Johannes Fischer , Eduards Mamlins , Aleksandar Radujkovic , Guido Kobbe , Julian Kirchner , Peter Minko , Kathrin Nachtkamp , Paul Jäger , Christina Antke , Frederik L. Giesel , Sascha Dietrich , Gerald Antoch , Kai Jannusch
{"title":"[18F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis","authors":"Helena A. Peters ,&nbsp;Ben-Niklas Bärmann ,&nbsp;Emil Novruzov ,&nbsp;Daniel Weiss ,&nbsp;Matthias Boschheidgen ,&nbsp;Vivien Lorena Ivan ,&nbsp;Nora Liebers ,&nbsp;Johannes Fischer ,&nbsp;Eduards Mamlins ,&nbsp;Aleksandar Radujkovic ,&nbsp;Guido Kobbe ,&nbsp;Julian Kirchner ,&nbsp;Peter Minko ,&nbsp;Kathrin Nachtkamp ,&nbsp;Paul Jäger ,&nbsp;Christina Antke ,&nbsp;Frederik L. Giesel ,&nbsp;Sascha Dietrich ,&nbsp;Gerald Antoch ,&nbsp;Kai Jannusch","doi":"10.1016/j.ejro.2025.100663","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>The aim of this study is to evaluate the potential of [<sup>18</sup>F]FDG-PET/CT in terms of prognostic value and treatment monitoring in relapsed / refractory diffuse large B-cell lymphoma (DLBCL)-patients treated with chimeric antigen receptor T-cell (CAR-T) therapy.</div></div><div><h3>Material &amp; methods</h3><div>Forty-eight [<sup>18</sup>F]FDG-PET/CT scans, acquired at pre-defined time points (t<sub>0</sub> – t<sub>2</sub>) of 18 DLBCL-patients (mean age: 60 ± 12 years) treated with CAR-T cell therapy were retrospectively enrolled. Median time of follow-up was ten months (IQR 6–16) following CAR-T cell infusion. SUV<sub>max</sub>, sum of the product of diameters (SPD), Deauville score (DS) and Lugano classification (LC) were evaluated. Clinical parameters (age, sex) were obtained. Survival time analyses for progression-free survival (PFS) and overall survival (OS) were calculated, the latter by using the Kaplan-Meier method and Cox regression including a hazard ratio (HR). <em>P</em> values below 0.05 were defined as statistically significant. 95 %-confidence intervals (CI) were calculated.</div></div><div><h3>Results</h3><div>Patients with a SUV<sub>max</sub>&gt; 9.0 at t<sub>0</sub> (median as threshold value) had a significantly shorter PFS (<em>p</em> = 0.04) and OS (<em>p</em> &lt; 0.01). According to LC, a progressive disease (PD) at t<sub>1</sub> (<em>p</em> = 0.02) and t<sub>2</sub> (<em>p</em> &lt; 0.01) was correlated with a reduced OS. SUV<sub>max</sub> &gt; 9.0 at t<sub>0</sub> (<em>p</em> = 0.03, HR = 7.0, CI: 1.3–40.5) and DS &gt; 3 at t<sub>1</sub> (<em>p</em> = 0.04, HR = 8.2, CI: 1.1–61.3) were associated with an increased risk of a PD.</div></div><div><h3>Conclusion</h3><div>SUV<sub>max</sub> of [<sup>18</sup>F]FDG-PET/CT seems to be useful as a prognostic marker in DLBCL-patients undergoing CAR-T cell therapy. Furthermore, scores of clinical established Deauville classification and Lugano response criteria acquired at post-CAR-T [<sup>18</sup>F]FDG-PET/CT might be an indicator for early therapy failure.</div></div>","PeriodicalId":38076,"journal":{"name":"European Journal of Radiology Open","volume":"14 ","pages":"Article 100663"},"PeriodicalIF":1.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Radiology Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352047725000309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

The aim of this study is to evaluate the potential of [18F]FDG-PET/CT in terms of prognostic value and treatment monitoring in relapsed / refractory diffuse large B-cell lymphoma (DLBCL)-patients treated with chimeric antigen receptor T-cell (CAR-T) therapy.

Material & methods

Forty-eight [18F]FDG-PET/CT scans, acquired at pre-defined time points (t0 – t2) of 18 DLBCL-patients (mean age: 60 ± 12 years) treated with CAR-T cell therapy were retrospectively enrolled. Median time of follow-up was ten months (IQR 6–16) following CAR-T cell infusion. SUVmax, sum of the product of diameters (SPD), Deauville score (DS) and Lugano classification (LC) were evaluated. Clinical parameters (age, sex) were obtained. Survival time analyses for progression-free survival (PFS) and overall survival (OS) were calculated, the latter by using the Kaplan-Meier method and Cox regression including a hazard ratio (HR). P values below 0.05 were defined as statistically significant. 95 %-confidence intervals (CI) were calculated.

Results

Patients with a SUVmax> 9.0 at t0 (median as threshold value) had a significantly shorter PFS (p = 0.04) and OS (p < 0.01). According to LC, a progressive disease (PD) at t1 (p = 0.02) and t2 (p < 0.01) was correlated with a reduced OS. SUVmax > 9.0 at t0 (p = 0.03, HR = 7.0, CI: 1.3–40.5) and DS > 3 at t1 (p = 0.04, HR = 8.2, CI: 1.1–61.3) were associated with an increased risk of a PD.

Conclusion

SUVmax of [18F]FDG-PET/CT seems to be useful as a prognostic marker in DLBCL-patients undergoing CAR-T cell therapy. Furthermore, scores of clinical established Deauville classification and Lugano response criteria acquired at post-CAR-T [18F]FDG-PET/CT might be an indicator for early therapy failure.
[18]FDG-PET/CT对CAR-T细胞治疗的dlbcl患者预后的影响
本研究的目的是评估[18F]FDG-PET/CT在复发/难治性弥漫性大b细胞淋巴瘤(DLBCL)患者接受嵌合抗原受体t细胞(CAR-T)治疗的预后价值和治疗监测方面的潜力。材料,方法回顾性纳入18例接受CAR-T细胞治疗的dlbcl患者(平均年龄:60 ± 12岁)在预定时间点(0 - t2)获得的48张[18F]FDG-PET/CT扫描。CAR-T细胞输注后的中位随访时间为10个月(IQR 6-16)。对SUVmax、直径积和(SPD)、Deauville评分(DS)和Lugano分类(LC)进行评价。获得临床参数(年龄、性别)。计算无进展生存期(PFS)和总生存期(OS)的生存时间分析,后者采用Kaplan-Meier法和Cox回归,包括风险比(HR)。P值小于0.05定义为有统计学意义。计算95 %置信区间(CI)。结果在t0(中位数为阈值)时SUVmax>; 9.0的患者PFS (p = 0.04)和OS (p <; 0.01)显著缩短。根据LC, t1 (p = 0.02)和t2 (p <; 0.01)的进展性疾病(PD)与OS降低相关。SUVmax >; 9.0 at 0 (p = 0.03,HR = 7.0, CI: 1.3-40.5)和DS >; 3 at t1 (p = 0.04,HR = 8.2, CI: 1.1-61.3)与PD风险增加相关。结论FDG-PET/CT的suvmax [18F]可作为dlbcl患者接受CAR-T细胞治疗的预后指标。此外,car - t后FDG-PET/CT获得的临床建立的Deauville分级和Lugano反应标准评分[18F]可能是早期治疗失败的一个指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Radiology Open
European Journal of Radiology Open Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
4.10
自引率
5.00%
发文量
55
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信